Page 38 - 南京医科大学学报自然科学版
P. 38
第41卷第4期
·508 · 南 京 医 科 大 学 学 报 2021年4月
通过增加肝癌细胞抗原递呈组件表达,提高抗肿瘤 view of preclinical and clinical evidence[J]. Clin Cancer
免疫,但同时上调PD⁃L1来改变肿瘤免疫逃逸。具体 Res,2014,20(21):5384-5391
机制可能涉及到相关通路使肿瘤浸润性T细胞表达 [9] TSUCHIYA N,SAWADA Y,ENDO I,et al. Potentiality
升高,释放干扰素⁃γ从而诱导PD⁃L1表达增加 [17-18] 。 of immunotherapy against hepatocellular carcinoma[J].
World J Gastroenterol,2015,21(36):10314-10326
同时有研究指出,使用PD⁃L1阻断剂能够减少肝癌中
[10] SMYTH M J,NGIOW S F,RIBAS A,et al. Combination
[19]
干扰素⁃γ引起的CD8 T细胞凋亡 。但都需要进一
+
cancer immunotherapies tailored to the tumour microenvi⁃
步动物实验验证。
ronment[J]. Nat Rev Clin Oncol,2016,13(3):143-158
综上所述,本研究显示洛铂可以提高肝癌患者 [11] PATEL S P,KURZROCK R. PD⁃L1 expression as a pre⁃
抗肿瘤免疫,可能是通过上调肝癌细胞抗原递呈组 dictive biomarker in cancer immunotherapy[J]. Mol Can⁃
件表达,增强肿瘤免疫原性导致。同时洛铂能够上 cer Ther,2015,14(4):847-856
调肝癌细胞PD⁃L1表达,其机制可能涉及AKT信号 [12] TAUBE J M,KLEIN A,BRAHMER J R,et al. Associa⁃
通路。为洛铂等细胞毒性抗肿瘤药物联合PD⁃L1免 tion of PD⁃1,PD⁃1 ligands,and other features of the tu⁃
疫检查点抑制剂治疗肝癌提供了可能。 mor immune microenvironment with response to anti⁃PD⁃1
therapy[J]. Clin Cancer Res,2014,20(19):5064-5074
[参考文献]
[13] FOURNEL L,WU Z,STADLER N,et al. Cisplatin in⁃
[1] TORRE L A,BRAY F,SIEGEL R L,et al. Global cancer creases PD⁃L1 expression and optimizes immune check⁃
statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108 point blockade in non⁃small cell lung cancer[J]. Cancer
[2] FENG R M,ZONG Y N,CAO S M,et al. Current cancer Lett,2019,464:5-14
situation in China:good or bad news from the 2018 global [14] TRAN L,ALLEN C T,XIAO R,et al. Cisplatin alters an⁃
cancer statistics?[J]. Cancer Commun(Lond),2019,39 titumor immunity and synergizes with PD⁃1/PD⁃L1 inhibi⁃
(1):22 tion in head and neck squamous cell carcinoma[J]. Can⁃
[3] ZHOU M,WANG H,ZENG X,et al. Mortality,morbidity, cer Immunol Res,2017,5(12):1141-1151
and risk factors in China and its provinces,1990⁃2017:a [15] VAN DER KRAAK L,GOEL G,RAMANAN K,et al. 5⁃
systematic analysis for the Global Burden of Disease Fluorouracil upregulates cell surface B7⁃H1(PD⁃L1)ex⁃
Study 2017[J]. Lancet,2019,394(1204):1145-1158 pression in gastrointestinal cancers[J]. J Immunother
[4] 吴金道,韩国勇,陆 森,等. 肝动脉栓塞化疗术联合索 Cancer,2016,4:65
拉菲尼对比单纯介入术治疗原发性肝癌的临床观察 [16] PENG J,HAMANISHI J,MATSUMURA N,et al. Chemo⁃
[J]. 南京医科大学学报(自然科学版),2015,35(12): therapy induces programmed cell death⁃ligand 1 overex⁃
1739-1742 pression via the nuclear factor⁃κB to foster an immunosup⁃
[5] QIN S,CHENG Y,LIANG J,et al. Efficacy and safety of pressive tumor microenvironment in ovarian cancer[J].
the FOLFOX4 regimen versus doxorubicin in Chinese pa⁃ Cancer Res,2015,75(23):5034-5045
tients with advanced hepatocellular carcinoma:a sub⁃ [17] GRABOSCH S,BULATOVIC M,ZENG F,et al. Cisplatin
group analysis of the EACH study[J]. Oncologist,2014, ⁃ induced immune modulation in ovarian cancer mouse
models with distinct inflammation profiles[J]. Oncogene,
19(11):1169-1178
[6] QIN S K,BAI Y X,LIM H Y,et al. Randomized,multi⁃ 2019,38(13):2380-2393
center,open⁃label study of oxaliplatin plus fluorouracil/ [18] BALOG J,HACKLER L J,KOVÁCS A K,et al. Single
leucovorin versus doxorubicin as palliative chemotherapy cell mass cytometry revealed the immunomodulatory ef⁃
+
in patients with advanced hepatocellular carcinoma from fect of cisplatin via downregulation of splenic CD44 ,IL⁃
+
17A MDSCs and promotion of circulating IFN⁃ γ+ my⁃
Asia[J]. J Clin Oncol,2013,31(28):3501-3508
[7] HODGE J W,GARNETT C T,FARSACI B,et al. Chemo⁃ eloid cells in the 4T1 metastatic breast cancer model[J].
therapy⁃induced immunogenic modulation of tumor cells Int J Mol Sci,2019,21(1):170
[19] SHI F,SHI M,ZENG Z,et al. PD⁃1 and PD⁃L1 upregula⁃
enhances killing by cytotoxic T lymphocytes and is dis⁃
tinct from immunogenic cell death[J]. Int J Cancer, tion promotes CD8(+)T⁃cell apoptosis and postoperative
2013,133(3):624-636 recurrence in hepatocellular carcinoma patients[J]. Int J
[8] DE BIASI A R,VILLENA⁃VARGAS J,ADUSUMILLI P Cancer,2011,128(4):887-896
[收稿日期] 2020-10-26
S. Cisplatin⁃induced antitumor immunomodulation:a re⁃